Shah v. Upjohn Co.

922 F. Supp. 15, 5 Am. Disabilities Cas. (BNA) 820, 1995 U.S. Dist. LEXIS 17547, 1995 WL 839600
CourtDistrict Court, W.D. Michigan
DecidedOctober 25, 1995
Docket1:94-cv-00783
StatusPublished
Cited by4 cases

This text of 922 F. Supp. 15 (Shah v. Upjohn Co.) is published on Counsel Stack Legal Research, covering District Court, W.D. Michigan primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Shah v. Upjohn Co., 922 F. Supp. 15, 5 Am. Disabilities Cas. (BNA) 820, 1995 U.S. Dist. LEXIS 17547, 1995 WL 839600 (W.D. Mich. 1995).

Opinion

OPINION AND ORDER ON DEFENDANTS MOTION FOR SUMMARY JUDGMENT

MILES, Senior District Judge.

In this action filed under the Americans With Disabilities Act (“ADA”), plaintiff Jyoti Shah alleges that defendant The Upjohn Company (“Upjohn”) violated that statute by failing to accommodate her through reassignment and by ultimately filing her from her employment as a research biochemist because — she alleges — she became allergic to her job. Upjohn has filed a motion for summary judgment, which plaintiff has opposed. For the following reasons, the court hereby GRANTS the Upjohn’s motion and dismisses this action with prejudice. 1

I

In February, 1980, Shah, a Kalamazoo, Michigan resident who holds a bachelor’s degree in chemistry, was hired by Upjohn to work as a biochemistry assistant. In 1984, Shah was promoted to the position of biochemist. In 1987, she was again promoted, this time to the position of research biochemist. Although Shah’s complaint alleges that this position “initially consisted of research and writing,” Complaint, ¶7, she has not disputed that the position of research biochemist is a position which requires laboratory work. Shah Dep. at 143^4.

In June, 1989, Dr. Greg Szpunar became the Director of Drug Metabolism and obtained supervisory authority over Shah, who worked in this group. Complaint, ¶ 9. Shortly thereafter, according to Shah, her career at Upjohn began to falter. Plaintiffs Brief at 2. In August, 1989, after disagreeing with Szpunar over ratings which she received in a performance appraisal, Shah became upset and leveled tacit threats to leave the unit. Memo, 1989 Performance Appraisal (attached as exhibit to Plaintiffs Brief). 2

In June, 1990, Shah underwent a routine physical examination at Upjohn’s Occupational Health (hereinafter “OH”) clinic. A blood test completed as part of the examination revealed an elevated level of eosinophils, known as eosinophilia (hereinafter “EOS”). Complaint, ¶ 10. According to Dr. Kenneth Rosenman of the Michigan State University School of Medicine, EOS may be defined as follows:

We have different types of white cells in our body. And one type of white cell is called an eosinophil. And so [EOS] is an increased number of that particular type of white cell. It’s not cancer. Sometimes people think of white cells, they think of leukemia. This just refers to an increase in this type of cell that you typically see with allergies or exposure to certain parasites.

Rosenman Dep. at 9.

In July, 1990, after Shah’s EOS was detected, Dr. Daniel Bouwman of Upjohn’s OH clinic referred her to Dr. Marshall A. MacDonald, an allergist, for further evaluation. MacDonald saw Shah on July 3, 1990. On August 10, 1990, MacDonald reported to Bouwman that an allergic investigation “failed to show any reason for the itching and [EOS].” Bouwman Aff., Ex. 1. However, because Shah’s EOS had disappeared during a four-week period in which she had apparently been out of the lab, MacDonald suggested that Shah avoid working with four specified chemicals which he described as “possible allergens.” Id. With these restrictions in mind, Shah was released to return to *18 the laboratory. Bouwman also arranged for Upjohn’s environmental services to check Shah’s work area to make sure that her ventilating hood was functioning properly and to assess her work area to make sure exposure to chemicals was limited. Bouw-man Aff., ¶ 8.

Shah alleges that upon returning to the laboratory, she again began to experience adverse health effects. Upjohn admits that by early 1991, Shah’s EOS had returned. Bouwman then referred Shah to Dr. Raymond Lord, a hematologist, who evaluated Shah in February, 1991. At the time of Lord’s examination, Shah’s EOS was mild and asymptomatic, although she reported having experienced itching and fatigue in May, 1990. Lord Dep. at 6-7. 3 Lord sent a report to Bouwman in which he explained that he had “rul[ed] out any serious reason for the [EOS]” and that

The eosinophils are mature and would likely, therefore, be a secondary [EOS] to some environmental stimulus. This is not a harmful event in her case, and I do not see at this point any reason to change her lifestyle or occupation on this basis....

Bouwman Aff., Ex. 3. Lord’s report also explained that

[M]any times [EOS] is secondary to a stimulus of which thorough investigation still does not show why the [EOS] is present. Also, in general, [EOS] is usually a benign course that does not cause long-term harmful sequelae.

Id. Lord noted that he had reassured Shah that her [EOS] “did not mean the beginning of leukemia or a lymphoma” and that she showed no evidence of either of these diseases. Id.

In September, 1991, Shah saw Bouwman in the OH clinic, complaining of fatigue and eye irritation. Bouwman decided to consult further with Lord. After reviewing Shah’s blood work, Lord reported to Bouwman in October, 1991 that Shah had the impression that her [EOS] was due to her laboratory exposure; however, Lord stated that this view was “not too objective and has a lot of subjective interpretation” by Shah. Bouw-man Aff., ¶ 13, and Ex. 4. Lord suggested that Shah be asked to participate in what amounted to a blind trial, whereby she would be asked to keep a diary of her energy level, symptoms, activities, and particular chemicals to which she was exposed. During this period, Shah’s eosinophil count would be monitored without informing her of the results. Id., Ex. 4. Dr. Bouwman discussed this proposal with Shah, who said that she would let him know if it was workable for her. Bouwman Aff., ¶ 15.

Shah returned to see Lord again on March 31,1992. This time, she described symptoms of nausea, vomiting, dizziness, headaches, skin rash, fatigue, and difficulty with coordination. Lord Dep. at 15. Shah alleges that after that visit, Lord recommended that she be assigned to work outside the laboratory. Complaint, ¶ 18. However, an April 13, 1992 letter written by Lord to Bouwman indicates that he recommended only that Shah be assigned to work outside the chemical laboratory. Bouwman Aff., Ex. 5. Although no allergen had been identified, Lord believed, based on her reports, that Shah’s EOS was work-related. Id. at 41.

Bouwman saw Shah in the OH clinic on April 17, 1992. Shah admitted that she had not kept the diary which had been suggested by Lord five months earlier. 4 However, Bouwman nonetheless discussed Shah’s situation with management and then decided to refer her to Dr. David Garabrant, a specialist in occupational medicine at the University of Michigan’s School of Public Health and School of Medicine in Ann Arbor. Bouwman Aff., ¶ s 17-18.

Garabrant evaluated Shah on June 26, 1992. Although Shah alleges that he found a “temporal relationship” between her labora *19 tory exposure and her EOS, Complaint, ¶ 20, his report to Bouwman stated in more detail as follows:

The etiology of her [EOS] is not clear.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Barber v. Pepsi-Cola Personnel, Inc.
78 F. Supp. 2d 683 (W.D. Michigan, 1999)
White v. Boehringer Mannheim Corp.
28 F. Supp. 2d 527 (S.D. Indiana, 1998)

Cite This Page — Counsel Stack

Bluebook (online)
922 F. Supp. 15, 5 Am. Disabilities Cas. (BNA) 820, 1995 U.S. Dist. LEXIS 17547, 1995 WL 839600, Counsel Stack Legal Research, https://law.counselstack.com/opinion/shah-v-upjohn-co-miwd-1995.